Charles River Joins Consortium to Advance Organ-On-A-Chip Technology

The NXTGEN HIGHTECH program drives the development and standardization of organ-on-a-chip technology. The Dutch consortium brings together more than 330 parties from industry and knowledge institutes to advance a range of next-generation technologies and to establish scalable, viable market pipelines.

The aim of organ-on-a-chip technology is to mimic human physiology, presenting a biologically relevant in vitro testing environment which maintains tissue-specific functions. In this way, it is possible to facilitate early in vitro testing of how a therapeutic might affect human cells with a functional readout.